These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 27871910)

  • 1. Pharmacological studies on the NOP and opioid receptor agonist PWT2-[Dmt
    Cerlesi MC; Ding H; Bird MF; Kiguchi N; Ferrari F; Malfacini D; Rizzi A; Ruzza C; Lambert DG; Ko MC; Calo G; Guerrini R
    Eur J Pharmacol; 2017 Jan; 794():115-126. PubMed ID: 27871910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dmt1]N/OFQ(1-13)-NH2: a potent nociceptin/orphanin FQ and opioid receptor universal agonist.
    Molinari S; Camarda V; Rizzi A; Marzola G; Salvadori S; Marzola E; Molinari P; McDonald J; Ko MC; Lambert DG; Calo' G; Guerrini R
    Br J Pharmacol; 2013 Jan; 168(1):151-62. PubMed ID: 22827708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spinal antinociceptive effects of the novel NOP receptor agonist PWT2-nociceptin/orphanin FQ in mice and monkeys.
    Rizzi A; Sukhtankar DD; Ding H; Hayashida K; Ruzza C; Guerrini R; Calò G; Ko MC
    Br J Pharmacol; 2015 Jul; 172(14):3661-70. PubMed ID: 25828800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives.
    Rizzi A; Malfacini D; Cerlesi MC; Ruzza C; Marzola E; Bird MF; Rowbotham DJ; Salvadori S; Guerrini R; Lambert DG; Calo G
    Br J Pharmacol; 2014 Sep; 171(17):4138-53. PubMed ID: 24903280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative biochemical and pharmacological characterization of a novel, NOP receptor selective hexapeptide, Ac-RYYRIR-ol.
    Bojnik E; Babos F; Fischetti C; Magyar A; Camarda V; Borsodi A; Bajusz S; Calo' G; Benyhe S
    Brain Res Bull; 2010 Mar; 81(4-5):477-83. PubMed ID: 19800951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor.
    Carrà G; Rizzi A; Guerrini R; Barnes TA; McDonald J; Hebbes CP; Mela F; Kenigs VA; Marzola G; Rizzi D; Gavioli E; Zucchini S; Regoli D; Morari M; Salvadori S; Rowbotham DJ; Lambert DG; Kapusta DR; Calo' G
    J Pharmacol Exp Ther; 2005 Mar; 312(3):1114-23. PubMed ID: 15509719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations.
    Ferrari F; Cerlesi MC; Malfacini D; Asth L; Gavioli EC; Journigan BV; Kamakolanu UG; Meyer ME; Yasuda D; Polgar WE; Rizzi A; Guerrini R; Ruzza C; Zaveri NT; Calo G
    Eur J Pharmacol; 2016 Dec; 793():1-13. PubMed ID: 27780725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel and facile synthesis of tetra branched derivatives of nociceptin/orphanin FQ.
    Guerrini R; Marzola E; Trapella C; Pela' M; Molinari S; Cerlesi MC; Malfacini D; Rizzi A; Salvadori S; Calo' G
    Bioorg Med Chem; 2014 Jul; 22(14):3703-12. PubMed ID: 24878361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo pharmacological characterization of the nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-ol.
    Gündüz O; Rizzi A; Baldisserotto A; Guerrini R; Spagnolo B; Gavioli EC; Kocsis L; Magyar A; Benyhe S; Borsodi A; Calò G
    Eur J Pharmacol; 2006 Jun; 539(1-2):39-48. PubMed ID: 16682024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel potent agonist [(pF)Phe4,Aib7,Aib11,Arg14,Lys15]N/OFQ-NH2 and antagonist [Nphe1,(pF)Phe4,Aib7,Aib11,Arg14,Lys15]N/OFQ-NH2 of nociceptin/orphanin FQ receptor.
    Peng YL; Chang M; Dong SL; Li W; Han RW; Fu GX; Chen Q; Wang R
    Regul Pept; 2006 May; 134(2-3):75-81. PubMed ID: 16516988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo).
    Bird MF; Cerlesi MC; Brown M; Malfacini D; Vezzi V; Molinari P; Micheli L; Di Cesare Mannelli L; Ghelardini C; Guerrini R; Calò G; Lambert DG
    PLoS One; 2016; 11(6):e0156897. PubMed ID: 27272042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure activity studies of nociceptin/orphanin FQ(1-13)-NH2 derivatives modified in position 5.
    Guerrini R; Marzola E; Trapella C; Pacifico S; Cerlesi MC; Malfacini D; Ferrari F; Bird MF; Lambert DG; Salvadori S; Calo G
    Bioorg Med Chem; 2015 Apr; 23(7):1515-20. PubMed ID: 25716007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24.
    Fischetti C; Camarda V; Rizzi A; Pelà M; Trapella C; Guerrini R; McDonald J; Lambert DG; Salvadori S; Regoli D; Calo' G
    Eur J Pharmacol; 2009 Jul; 614(1-3):50-7. PubMed ID: 19445927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding of the novel radioligand [(3)H]UFP-101 to recombinant human and native rat nociceptin/orphanin FQ receptors.
    Ibba M; Kitayama M; McDonald J; Calo G; Guerrini R; Farkas J; Toth G; Lambert DG
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Dec; 378(6):553-61. PubMed ID: 18807245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor.
    Calo G; Rizzi A; Rizzi D; Bigoni R; Guerrini R; Marzola G; Marti M; McDonald J; Morari M; Lambert DG; Salvadori S; Regoli D
    Br J Pharmacol; 2002 May; 136(2):303-11. PubMed ID: 12010780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands.
    Guerrini R; Caló G; Lambert DG; Carrá G; Arduin M; Barnes TA; McDonald J; Rizzi D; Trapella C; Marzola E; Rowbotham DJ; Regoli D; Salvadori S
    J Med Chem; 2005 Mar; 48(5):1421-7. PubMed ID: 15743186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor.
    Rizzi A; Spagnolo B; Wainford RD; Fischetti C; Guerrini R; Marzola G; Baldisserotto A; Salvadori S; Regoli D; Kapusta DR; Calo G
    Peptides; 2007 Jun; 28(6):1240-51. PubMed ID: 17532097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the activity of a novel nociceptin/orphanin FQ analogue at recombinant human nociceptin/orphanin FQ receptors expressed in Chinese hamster ovary cells.
    Wright KE; McDonald J; Barnes TA; Rowbotham DJ; Guerrini R; Calo' G; Lambert DG
    Neurosci Lett; 2003 Aug; 346(3):145-8. PubMed ID: 12853105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological profile of the cyclic nociceptin/orphanin FQ analogues c[Cys10,14]N/OFQ(1-14)NH2 and c[Nphe1,Cys10,14]N/OFQ(1-14)NH2.
    Kitayama M; Barnes TA; Carra G; McDonald J; Calo G; Guerrini R; Rowbotham DJ; Smith G; Lambert DG
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Dec; 368(6):528-37. PubMed ID: 14598020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic-versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands.
    Asth L; Ruzza C; Malfacini D; Medeiros I; Guerrini R; Zaveri NT; Gavioli EC; Calo' G
    Neuropharmacology; 2016 Jun; 105():434-442. PubMed ID: 26867504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.